Injection training for the 2026 at-home Leqembi regimen teaches patients and care partners to give weekly shots safely after supervised clinic doses. Leqembi Iqlik (lecanemab-irmb) is a weekly anti-amyloid shot for early Alzheimer's, and training focuses on dose handling, injection sites, eligibility, and MRI safety checks. Use the visit with an Alzheimer's specialist to confirm home readiness, site technique, and monitoring plans. The FDA approved a 500-mg weekly initiation dose on July 13, 2026.
Each weekly initiation dose uses two consecutive 250-mg autoinjector shots of about 15 seconds each, as described in the FDA approval notice. Eisai and Biogen history records a 360-mg weekly maintenance dose approved Aug. 29, 2025. It applies after 18 months of IV or subcutaneous starting treatment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- When are you ready to inject at home?
- Where do you place the autoinjector?
- Who qualifies for a home start?
- Why does hospital monitoring continue?
- What does a Nurse Educator cover?
When are you ready to inject at home?
Home use starts only after clinic supervision. FDA prescribing information requires at least two consecutive subcutaneous doses under direct provider guidance. Therapy starts under supervision with training on preparation and administration.
Bring these checks to the visit. Read each answer into your home plan. Keep the specialist contact for technique questions.
- Did I complete two consecutive doses under direct provider guidance?
- What preparation and administration steps must I demonstrate first?
- Who decides I am ready for home use?
Where do you place the autoinjector?
For self-injection, use the abdomen or upper thigh and avoid the 2-inch area around the navel. The back of the upper arm is approved only when a provider or caregiver gives the shot, as listed on the Drugs.com dosage page. Each weekly initiation dose uses two back-to-back autoinjector shots.
Ask the specialist to watch the full sequence before home use. Ask the specialist to watch site selection and injection timing. Ask how to record which site you used and what to report at follow-up.
Who qualifies for a home start?
Treatment is limited to adults with mild cognitive impairment or mild dementia due to Alzheimer's with confirmed amyloid-beta pathology. The National Library of Medicine DailyMed label defines that trial population as the approved group. Testing for ApoE epsilon-4 is needed before starting because homozygotes face higher rates of symptomatic and serious ARIA.
PrescriberPoint's summary of FDA prescribing information calls for a baseline MRI plus scans after 1, 2, 3 and 6 months, detailed in the PrescriberPoint therapy summary. Ask whether amyloid testing is complete and documented. Ask what your ApoE result means for monitoring and whether MRI dates are booked.
Why does hospital monitoring continue?
Home dosing does not remove hospital monitoring. The FDA warns that Leqembi carries a boxed warning for ARIA brain swelling and bleeds that can be fatal.
It also warns of serious brain hemorrhages larger than 1 cm and added bleeding risk with anticoagulants. Tell the specialist about blood thinners and bleeding history before training. Ask which hospital handles urgent MRI and ARIA care during home treatment.
What does a Nurse Educator cover?
Eisai and Biogen's LEQEMBI Companion program offers Nurse Educators in person or virtually for device-only injection training. The Eisai program also offers an injection-tracking tool and insurance and financial-support help. Nurse training covers device use, not treatment decisions.
Keep dose changes, MRI results, and ARIA concerns with the prescribing specialist. Bring your MRI schedule, ApoE result, and full medication list to training. Confirm who to call for device questions and who to call for medical symptoms.
You Might Also Like
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: Questions Anti-Amyloid Treatment Patients Can Ask an Alzheimer’s Specialist
- MRI and ARIA Monitoring With At-Home Leqembi in 2026: Questions Anti-Amyloid Treatment Patients Can Ask an Alzheimer’s Specialist
- Cross-Cultural Dementia Risk Programs After LatAm-FINGERS 2026: Questions People With Mild Cognitive Impairment Can Discuss With a Clinician





